Patent No. 595405 Disclosed is a use of a compound of formula I, such as 2-{ [3-(3,4-dimethoxybenzyl)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)oxy} propanenitrile in the preparation of a medicament for the treatment and/or prevention of psychiatric disorders or neurological disorders, wherein the psychiatric disorders are chosen from anxiety, depression, mood disorders, insomnia, delusion disorders, obsessive disorders, psychoses, disorders related to schizophrenia, attention deficit hyperactivity disorders (ADHD) in hyperkinetic children, disorders related to the use of psychotropic substances, in particular in the case of abuse of a substance and/or of dependency on a substance, including alcohol dependence and/or nicotine dependence, stress, disorders related to illnesses of psychosomatic origin, panic attacks, epilepsy, memory disorders, cognitive disorders, in particular senile dementia or disorders related to Alzheimer's disease, and disorders of attention or of vigilance, ischaemia, disorders related to brain trauma or disorders related to acute or chronic neurodegenerative diseases, including chorea and Huntington's chorea, wherein the neurological disorders are reflected by movement anomalies or motor disorders associated with a pathology chosen from dyskinesia, Parkinson's disease, postencephalitic parkinsonism, dopasensitive dystonia, Shy-Drager syndrome, periodic limb movement disorder (PLMD) syndrome, periodic limb movements in sleep (PLMS) syndrome, Tourette's syndrome or restless legs syndrome (RLS).
